Literature DB >> 16495400

The long and the short of bone therapy.

Michael P Whyte.   

Abstract

Mesh:

Substances:

Year:  2006        PMID: 16495400     DOI: 10.1056/NEJMe068003

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Hot stuff--can't get enough.

Authors:  E Seeman
Journal:  Osteoporos Int       Date:  2006       Impact factor: 4.507

2.  Denosumab in postmenopausal osteoporosis: what the clinician needs to know.

Authors:  E Michael Lewiecki
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-02       Impact factor: 5.346

Review 3.  New understanding and treatments for osteoporosis.

Authors:  G Mazziotti; J Bilezikian; E Canalis; D Cocchi; A Giustina
Journal:  Endocrine       Date:  2012-02       Impact factor: 3.633

Review 4.  Future directions of bone-targeted therapy for metastatic breast cancer.

Authors:  Tomifumi Onishi; Naoki Hayashi; Richard L Theriault; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Nat Rev Clin Oncol       Date:  2010-08-31       Impact factor: 66.675

Review 5.  Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.

Authors:  T M Cox; J M F G Aerts; N Belmatoug; M D Cappellini; S vom Dahl; J Goldblatt; G A Grabowski; C E M Hollak; P Hwu; M Maas; A M Martins; P K Mistry; G M Pastores; A Tylki-Szymanska; J Yee; N Weinreb
Journal:  J Inherit Metab Dis       Date:  2008-05-23       Impact factor: 4.982

6.  Denosumab: an investigational drug for the management of postmenopausal osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Biologics       Date:  2008-12

Review 7.  Clinical development of anti-RANKL therapy.

Authors:  Edward M Schwarz; Christopher T Ritchlin
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

Review 8.  Bone Targeted Therapies for Bone Metastasis in Breast Cancer.

Authors:  Wajeeha Razaq
Journal:  J Clin Med       Date:  2013-10-14       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.